MedTrace Logo

Surgical Pembro +/- Olaparib w TMZ for rGBM

NCT05463848 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-03-04

No results posted yet for this study

Summary

This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

The names of the study interventions involved in this study are/is:

* Pembrolizumab
* Olaparib
* Temozolomide (Temodar)

Conditions

Interventions

DRUG

Pembrolizumab

Intravenous infusion

DRUG

Olaparib

Pill taken by mouth

DRUG

Temozolomide

Pill taken by mouth

Sponsors & Collaborators

Principal Investigators

  • Luis N Gonzalez Castro, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-21
Primary Completion
2026-08-01
Completion
2027-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05463848 on ClinicalTrials.gov